Clinical and economic evaluation of pharmacists' contribution to XXXX care on a multi-disciplinary liver transplant team.

@entity1 @entity137
OBJECTIVES: We aimed to describe and to evaluate the clinical and economic implications of pharmacists' interventions as members of the liver transplant team for hospitalized liver recipients. METHODS: Retrospective descriptive and cost-benefit analysis of documented pharmacist interventions for hospitalized @entity1 from January 2010 to June 2012 was conducted. The type of drug-related problems (DRPs) was categorized. The clinical significance of pharmacist interventions was rated using five scales by two professionals. The cost avoidance was estimated based on the probability that an @entity137 ( @entity137 ) would have occurred without intervention using previously reported additional costs for @entity137 treatment. RESULTS: A total of 1,880 interventions were documented for 420 liver transplant recipients. The most common DRP was "need additional drug therapy" (42.6%), followed by "dosage problems" (23.5%). The most common drug class addressed by intervention was antimicrobials (51.4%). Most interventions were rated as more than clinically "significant". Analysis showed that pharmacist activities related to potential @entity137 prevention had a clear cost-benefit with a net cost-benefit     94,009 and a cost-benefit ratio of 3.8. CONCLUSION: This study demonstrated the positive impact of clinical pharmacists on the care of hospitalized liver transplant @entity1 in terms of both clinical and economic outcomes.
